Identification | Back Directory | [Name]
Carbamic acid, N-[(5S)-5-[[(2R,3S)-3-(formylhydroxyamino)-2-(2-methylpropyl)-1-oxohexyl]amino]-6-oxo-6-(2-thiazolylamino)hexyl]-, phenylmethyl ester | [CAS]
866924-39-2 | [Synonyms]
GW280264X,Carbamic acid Benzyl ((S)-5-((2R,3S)-3-(N-hydroxyformamido)-2-isobutylhexanamido)-6-oxo-6-(thiazol-2-ylamino)hexyl)carbamate Carbamic acid, N-[(5S)-5-[[(2R,3S)-3-(formylhydroxyamino)-2-(2-methylpropyl)-1-oxohexyl]amino]-6-oxo-6-(2-thiazolylamino)hexyl]-, phenylmethyl ester | [Molecular Formula]
C28H41N5O6S | [MDL Number]
MFCD33023416 | [MOL File]
866924-39-2.mol | [Molecular Weight]
575.72 |
Chemical Properties | Back Directory | [density ]
1.229±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMSO: soluble | [form ]
A crystalline solid | [pka]
8.27±0.50(Predicted) | [color ]
White to off-white |
Hazard Information | Back Directory | [Uses]
GW 280264X is a inhibitor of the metalloproteinase ADAM17. | [in vivo]
Pharmacological inhibition of ADAM10 and ADAM17 improves functional recovery after spinal cord injury (SCI)[3]. Animal Model: | C57BL/6 mice[3] | Dosage: | 100 ?μg/kg | Administration: | I.p. injected; every day for one week starting 4?h post-surgery | Result: | Showed significantly improved functional recovery compared to the control group.
|
| [IC 50]
ADAM17: 8 nM (IC50); ADAM10: 11.5 nM (IC50) | [storage]
Store at -20°C |
|
|